# Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma

> **NCT03535259** · PHASE2 · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 86 (actual)

## Conditions studied

- Hepatocellular Carcinoma, Radiotherapy, Sorafenib

## Interventions

- **RADIATION:** concurrent sorafenib and IMRT, followed sorafenib maintenance

## Key facts

- **NCT ID:** NCT03535259
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-08
- **Primary completion:** 2020-01-31
- **Final completion:** 2021-06-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535259, "Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03535259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*